Phibro Animal Health financials
$35.45−0.70%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '26 Jun 30 | Q3 '26 Mar 31 | Q2 '26 Dec 31 | Q1 '26 Sep 30 | Q4 '25 Jun 30 | Q3 '25 Mar 31 | Q2 '25 Dec 31 | Q1 '25 Sep 30 | Q4 '24 Jun 30 | Q3 '24 Mar 31 | Q2 '24 Dec 31 | Q1 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $396.7M | $383.5M | $373.9M | $363.9M | $378.7M | $347.8M | $309.3M | $260.4M | $273.2M | $263.2M | $249.9M | $231.3M |
| Gross profit | $134.4M | $125.7M | $132.7M | $119.8M | $110.0M | $104.6M | $101.9M | $83.5M | $87.2M | $79.6M | $78.6M | $67.7M |
| Gross margin | 33.9% | 32.8% | 35.5% | 32.9% | 29.0% | 30.1% | 32.9% | 32.1% | 31.9% | 30.2% | 31.5% | 29.3% |
| Operating income | $48.2M | $44.7M | $50.3M | $51.3M | $33.7M | $33.5M | $25.5M | $17.7M | $18.4M | $19.9M | $15.7M | -$726.0K |
| Net income | $21.7M | $24.0M | $27.5M | $26.5M | $17.2M | $20.9M | $3.2M | $7.0M | $752.0K | $8.4M | $1.3M | -$8.0M |
| Net margin | 5.5% | 6.3% | 7.3% | 7.3% | 4.5% | 6.0% | 1.0% | 2.7% | 0.3% | 3.2% | 0.5% | −3.5% |
| Diluted EPS | $0.53 | $0.59 | $0.67 | $0.65 | $0.42 | $0.51 | $0.08 | $0.17 | $0.02 | $0.21 | $0.03 | $-0.20 |
| EBITDA | $61.5M | $57.1M | $63.2M | $64.1M | $46.1M | $46.1M | $37.1M | $26.7M | $27.6M | $29.1M | $24.6M | $8.1M |
| Operating cash flow | $24.1M | $16.2M | $19.4M | $9.3M | $21.3M | $43.2M | $3.1M | $12.6M | $28.4M | $11.4M | $31.6M | $16.2M |
| Free cash flow | $5.2M | $890.0K | $8.3M | -$4.5M | $8.1M | $35.4M | -$4.7M | $3.0M | $15.4M | $1.7M | $20.6M | $8.7M |
| Diluted shares | 41.0M | 41.0M | 41.0M | 40.9M | 40.7M | 40.7M | 40.7M | 40.6M | 40.6M | 40.5M | 40.5M | 40.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $61.4M | $54.9M | $55.5M | $72.8M | $68.0M | $60.4M |
| Short-term investments | $20.6M | $22.5M | $19.0M | $12.5M | $9.0M | $10.0M |
| Total debt | $732.8M | $735.5M | $731.2M | $743.0M | $718.7M | $727.4M |
| Total assets | $1.50B | $1.45B | $1.41B | $1.39B | $1.36B | $1.32B |
| Total liabilities | $1.12B | $1.08B | $1.07B | $1.07B | $1.08B | $1.05B |
| Shareholders' equity | $385.5M | $361.8M | $332.4M | $311.7M | $285.7M | $266.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology